// App-Quantinova.ai

: Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

Researchers

Presenter

  • Miguel Quijada Álamo

Principal Investigators

  • Laura Z. Rassenti

  • Emanuela M. Ghia

  • Tuan Tran

  • Monica Spydell

  • Elsa Molina

  • Claudia Pérez Carretero

  • Luis A. Corchete

  • Teresa Gonzalez

  • Jesus Maria Hernandez-Rivas

  • Thomas J. Kipps

Medical Centers

  • Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA

  • Center for Novel Therapeutics, Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Department of Medicine, University Hospital of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

Locations

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Bruton tyrosine kinase

  • Interleukin-2

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved